- Conditions
- Acute Myeloid Leukemia (AML), Cancer
- Interventions
- Venetoclax, Azacitidine, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 43
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 13,957
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Trichosanthin, Zidovudine
- Drug
- Lead sponsor
- Genelabs Technologies
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- San Francisco, California • Miami, Florida • Tampa, Florida + 2 more
- Conditions
- CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
- Interventions
- brentuximab vedotin
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- 5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
- Interventions
- ladiratuzumab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
- Conditions
- Ovarian Cancer, Chemotherapeutic Toxicity
- Interventions
- Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet
- Dietary Supplement · Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Romiplostim, Predniso(lo)ne
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Long Beach, California • Peoria, Illinois • Fredericksburg, Virginia
- Conditions
- Actinic Keratosis
- Interventions
- Photodynamic therapy, Imiquimod
- Drug
- Lead sponsor
- Tennessee Clinical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
- Interventions
- Decitabine, Venetoclax, Calaspargase pegol-mknl
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Any Cancer Diagnosis
- Interventions
- Play Intervention, Questionnaires
- Behavioral · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 4 Years to 10 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetic Kidney Disease, Uncontrolled Hypertension
- Interventions
- Telehealth
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Follicular Lymphoma
- Interventions
- Rituximab, Neo Vax, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Giant Cell Arteritis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Boston, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2008
- U.S. locations
- 100
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab (Lucentis), 0.5mg ranibizumab
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer, Stereotactic Body Radiation Therapy
- Interventions
- GC4419, Placebo, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Drug · Radiation
- Lead sponsor
- Galera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Boston, Massachusetts • Morristown, New Jersey + 3 more
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
- Interventions
- Pirfenidone, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumor, Adult
- Interventions
- FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Ezatiostat Hydrochloride, Lenalidomide (Revlimid®)
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Maywood, Illinois • Bethesda, Maryland + 6 more
- Conditions
- HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
- Interventions
- Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
- Combination Product · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 32
- States / cities
- Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- clonazepam and paroxetine
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors
- Interventions
- Acasunlimab, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more